First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 804 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer MOST POPULAR Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with... March 2, 2021 EMA Recommends Extension of Indications for Olaparib September 24, 2020 Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic... March 25, 2021 FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer January 25, 2023 Load more HOT NEWS Transforming optimism: finding new ways to treat rare cancers Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning FDA Approves Acalabrutinib with Venetoclax for CLL or SLL Breast Cancer Survivors in Happy Romantic Relationships Are Healthier, Study Says
